Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Azacitidine maintenance in high-risk myeloid neoplasms post-transplant
NCT06900088Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of selinexor in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Recurrence Free Survival Rate at 2 years. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
selinexor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06900088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06900088.